VEGFA and ovarian carcinoma: Multiple vascular factors play an important role in angiogenesis, with vascular endothelial growth factors and receptors (VEGF-VEGFRs) among the most potent angiogenic systems1 in promoting the growth of solid organ malignancies.2 Therefore, anti-VEGF-VEGFR therapies have become the standards of care (SoC) for several solid malignant conditions including colorectal cancer, renal cancer, hepatocellular cancer and ovarian cancer.3